Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- BACBank of America Up
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
2 reports over 3h 14m-
CNBC Business You're reading this Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says Strong bullish +42



